Jan 23, 2026
•
7 min read
Janux secures $850M BMS deal; Corxel raises $287M for oral obesity; Mendra launches with $82M.
Jan 22, 2026
FDA drafts MRD guidance for myeloma; IntraBio hits Phase 3 endpoints; BioCryst/Astria merger set to close.
Jan 21, 2026
Gedatolisib earns Priority Review with a July 17 PDUFA date; Worldwide acquires Catalyst amid CRO consolidation. Plus oncology updates and J&J earnings to watch.
Jan 20, 2026
Absorbing Friday’s Ionis, Blueprint, and Krystal raises, plus what to watch ahead of J&J’s Q4 print on Stelara erosion and MedTech recovery.
Post-JPM reset · $2.5B capital clear-out · JNJ/Abbott earnings setup
Financing floods, Sarepta’s reality check, PBMs reposition, and the true cost of capital emerges.
JPM Day 3: Intuitive signals staffing recovery, Vertex locks in pain dominance, and the FDA’s new digital stance.
Lilly’s access strategy, AbbVie’s manufacturing signal, and what it means for license-to-operate in 2026.
Deep dive into Amgen’s "Springboard" year, Vertex’s launch metrics, and the new RNAi duopoly.
Lilly–Ventyx sets valuation context, Aktis IPO provides a benchmark, and policy risk stays in check.
Lilly buys Ventyx ($1.2B) · Aktis prices upsized IPO · Parabilis & Alveus raise big · 340B rebate blocked · Krystal de-risks inhaled gene therapy.
Capital Markets Re-Open | Jazz/Zymeworks Data Due | Executive Shuffle at SAB Bio
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
